EORTC led intergroup trial investigates Imatinib failure-free survival in patients with GIST
Interim results of an EORTC intergroup trial have confirmed that adjuvant imatinib impacts short-term freedom from relapse in patients with localized, surgically resected, high/ intermediate-risk GIST. In the high-risk subgroup, ...
May 29, 2013
0
0